<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00176</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> The NIH Director is responsible for:  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;a&hyph;(1). Promulgating requirements as necessary to implement the  <!-- PJG 0012 frnewline --> NIH Guidelines;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;a&hyph;(2). Establishing and maintaining the RAC to carry out the  <!-- PJG 0012 frnewline --> responsibilities set forth in Section IV&hyph;C&hyph;2 (RAC membership is specified in its  <!-- PJG 0012 frnewline --> charter and in Section IV&hyph;C&hyph;2); and  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;a&hyph;(3). Establishing and maintaining ORDA to carry out the  <!-- PJG 0012 frnewline --> responsibilities defined in Section IV&hyph;C&hyph;3. <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section IV&hyph;C&hyph;1&hyph;b. Specific Responsibilities  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In carrying out the responsibilities set forth in this section, the NIH Director, or a designee shall weigh each proposed action through appropriate analysis and  <!-- PJG 0012 frnewline --> consultation to determine whether it complies with the NIH Guidelines and presents  <!-- PJG 0012 frnewline --> no significant risk to health or the environment.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1). Major Actions  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> To execute Major Actions, the NIH Director shall seek the advice of the RAC and  <!-- PJG 0012 frnewline --> provide an opportunity for public and Federal agency comment. Specifically, the  <!-- PJG 0012 frnewline --> Notice of Meeting and Proposed Actions to the NIH Guidelines shall be published  <!-- PJG 0012 frnewline --> in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  at least 15 days before the RAC meeting (not applicable for  <!-- PJG 0012 frnewline --> Expedited Review single patient human gene transfer experiments considered under  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI). The NIH Director's decision, at his/her discretion, may be  <!-- PJG 0012 frnewline --> published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  for 15 days of comment before final action is taken.  <!-- PJG 0012 frnewline --> The NIH Director's final decision, along with responses to public comments, shall  <!-- PJG 0012 frnewline --> be published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The RAC and Institutional Biosafety  <!-- PJG 0012 frnewline --> Committee Chairs shall be notified of the following decisions:  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(a). Changing containment levels for types of experiments that  <!-- PJG 0012 frnewline --> are specified in the NIH Guidelines when a Major Action is involved;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(b). Assigning containment levels for types of experiments that  <!-- PJG 0012 frnewline --> are not explicitly considered in the NIH Guidelines when a Major Action is involved;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(c). Promulgating and amending a list of classes of  <!-- PJG 0012 frnewline --> recombinant DNA molecules to be exempt from the NIH Guidelines because they  <!-- PJG 0012 frnewline --> consist entirely of DNA segments from species that exchange DNA by known  <!-- PJG 0012 frnewline --> physiological processes or otherwise do not present a significant risk to health or the  <!-- PJG 0012 frnewline --> environment;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(d). Permitting experiments specified by Section III&hyph;A;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(e). Certifying new host-vector systems with the exception of  <!-- PJG 0012 frnewline --> minor modifications of already certified systems (the standards and procedures for  <!-- PJG 0012 frnewline --> certification are described in Appendix I&hyph;II). Minor modifications constitute (e.g.,  <!-- PJG 0012 frnewline --> those of minimal or no consequence to the properties relevant to containment); and  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(f). Adopting other changes in the NIH Guidelines.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2). Minor Actions  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> NIH/ORDA shall carry out certain functions as delegated to it by the NIH Director  <!-- PJG 0012 frnewline --> (see Section IV&hyph;C&hyph;3). Minor Actions (as determined by NIH/ORDA in consultation  <!-- PJG 0012 frnewline --> with the RAC Chair and one or more RAC members, as necessary) will be  <!-- PJG 0012 frnewline --> transmitted to the RAC and Institutional Biosafety Committee Chairs:  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(a). Reviewing and approving certain experiments involving  <!-- PJG 0012 frnewline --> the deliberate transfer of recombinant DNA or DNA or RNA derived from  <!-- PJG 0012 frnewline --> recombinant DNA into one or more human subjects that qualify for the Accelerated  <!-- PJG 0012 frnewline --> Review process (see Section III&hyph;B&hyph;2);  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(b). Reviewing and approving minor changes to human gene  <!-- PJG 0012 frnewline --> transfer protocols under Section III&hyph;A&hyph;2 and III&hyph;B&hyph;2;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(c). Changing containment levels for experiments that are  <!-- PJG 0012 frnewline --> specified in Section III;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(d). Assigning containment levels for experiments not explicitly  <!-- PJG 0012 frnewline --> considered in the NIH Guidelines; and  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(e). Revising the Classification of Etiologic Agents for the  <!-- PJG 0012 frnewline --> purpose of these NIH Guidelines (see Section V&hyph;A). <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(f). Interpreting the NIH Guidelines for experiments to which the NIH Guidelines do not specifically assign containment levels;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(g). Setting containment under Sections III&hyph;C&hyph;1&hyph;d and III&hyph;C&hyph;2&hyph;  <!-- PJG 0012 frnewline --> b;  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(h). Approving minor modifications of already certified  <!-- PJG 0012 frnewline --> host-vector systems (the standards and procedures for such modifications are  <!-- PJG 0012 frnewline --> described in Appendix I&hyph;II);  <!-- PJG 0012 frnewline --> Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(i). Decertifying already certified host-vector systems;  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            